Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Frontline Ltd., a shipping company, engages in the seaborne transportation of crude oil and oil products worldwide. It owns and operates oil and product tankers. As of December 31, 2021, the company operated a fleet of 70 vessels. It is also involved in the charter, purchase, and sale of vessels. The company was founded in 1985 and is based in Hamilton, Bermuda.

Frontline Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WAYNE, PA., AUG. 20, 2025 (GLOBE NEWSWIRE) -- FRONTLINE EDUCATION, THE LEADING PROVIDER OF ADMINISTRATION SOFTWARE PURPOSE-BUILT FOR K-12, TODAY ANNOUNCED THE LAUNCH OF ITS DEAR FUTURE CAMPAIGN  A POWERFUL EXPRESSION OF THE COMPANY'S AI VISION AND COMMITMENT TO DRIVING THE NEXT ERA OF INNOVATION FOR SCHOOL DISTRICT OPERATIONS, BUILT IN CLOSE PARTNERSHIP WITH K-12 LEADERS TO ENSURE PROGRESS IS GUIDED BY THE VOICES OF THOSE IT SERVES.

FRONTLINE EDUCATION LAUNCHES AI VISION, BROUGHT TO LIFE BY DEAR FUTURE CAMPAIGN

SAFETY REVIEW COMMITTEE ENDORSES ESCALATION TO 160 MG TUS DOSING COHORTS WITH 120 MG, 80 MG, 40 MG TUS DOSING COMPLETED WITH NO DOSE-LIMITING TOXICITIES EXCELLENT SAFETY AND COMPLETE REMISSIONS (CRS) IN SOME OF THE MOST DIFFICULT-TO-TREAT AML POPULATIONS NO DOSE REDUCTIONS REQUIRED TO THE STANDARD-OF-CARE VEN/AZA WITH TUS DOSE COHORTS TUS+VEN+AZA TRIPLET CONTINUES TO ACHIEVE CRS AND MINIMAL RESIDUAL DISEASE (MRD)-NEGATIVITY WITH FAVORABLE SAFETY IN NEWLY DIAGNOSED AML PATIENTS APTOSE RECEIVES THIRD ADVANCE UNDER THE LOAN AGREEMENT WITH HANMI PHARMACEUTICAL SAN DIEGO AND TORONTO, AUG. 06, 2025 (GLOBE NEWSWIRE) -- APTOSE BIOSCIENCES INC. (APTOSE OR THE COMPANY) (OTC: APTOF, TSX: APS), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY DEVELOPING THE TUSPETINIB (TUS)-BASED TRIPLE DRUG FRONTLINE THERAPY TO TREAT PATIENTS WITH NEWLY DIAGNOSED AML, TODAY ANNOUNCED THAT THE COHORT SAFETY REVIEW COMMITTEE (CSRC) MONITORING APTOSE'S PHASE 1/2 TUSCANY TRIAL OF TUS IN COMBINATION WITH STANDARD OF CARE DOSING OF VENETOCLAX AND AZACITIDINE (TUS+VEN+AZA TRIPLET) HAS APPROVED ESCALATING FROM 120 MG TUS DOSE TO 160 MG TUS DOSE BASED ON ITS FAVORABLE REVIEW OF SAFETY AND EFFICACY DATA FROM PATIENTS IN THE FIRST THREE COHORTS (40 MG, 80 MG, AND 120 MG TUS DOSE LEVELS) OF THE TRIAL. ENROLLMENT IS OPEN FOR DOSING SUBJECTS AT THE 160 MG TUS DOSE LEVEL.

APTOSE ENROLLMENT IS OPEN FOR 160 MG DOSING COHORT OF TUSPETINIB IN PHASE 1/2 TUSCANY TRIAL OF FRONTLINE TRIPLE DRUG THERAPY

WAYNE, PA., JULY 28, 2025 (GLOBE NEWSWIRE) -- FRONTLINE EDUCATION, A LEADING PROVIDER OF ADMINISTRATION SOFTWARE PURPOSE-BUILT FOR K-12 EDUCATORS, TODAY ANNOUNCED THE APPOINTMENT OF JOEL SACKETT AS THE COMPANY'S NEW CHIEF PRODUCT OFFICER (CPO).

FRONTLINE EDUCATION NAMES JOEL SACKETT AS CHIEF PRODUCT OFFICER

DENVER, COLORADO--(NEWSFILE CORP. - JULY 22, 2025) - 247MARKETNEWS.COM, A PIONEER IN DIGITAL MEDIA DEDICATED TO THE SWIFT DISTRIBUTION OF FINANCIAL MARKET NEWS AND INFORMATION, REPORTS THAT SIYATA MOBILE (NASDAQ: SYTA), A GLOBAL DEVELOPER AND VENDOR OF MISSION-CRITICAL PUSH-TO-TALK OVER CELLULAR (POC) HANDSETS AND ACCESSORIES, ANNOUNCED THAT ITS FLAGSHIP SD7 DEVICE EARNED THE PRESTIGIOUS "VERIZON FRONTLINE VERIFIED" DESIGNATION. THIS MILESTONE OFFICIALLY QUALIFIES THE SD7 FOR USE BY FIRST RESPONDERS OPERATING ON VERIZON'S PUBLIC SAFETY NETWORK AND POSITIONS SIYATA AS A KEY COMMUNICATIONS PARTNER ACROSS ALL THREE MAJOR U.S. WIRELESS CARRIERS: VERIZON, T-MOBILE, AND AT&T.

24/7 MARKET NEWS: SIYATA MOBILE EARNS VERIZON FRONTLINE VERIFIED STATUS, NOW PROTECTING COMMUNITIES ACROSS ALL MAJOR U.S. NETWORKS

APPROVED FOR USE ON VERIZON FRONTLINE NETWORK FOR FIRST RESPONDERS VANCOUVER, BC , JULY 16, 2025 /PRNEWSWIRE/ -- SIYATA MOBILE INC. (NASDAQ: SYTA, SYTAW) ("SIYATA" OR THE "COMPANY"), A GLOBAL DEVELOPER AND VENDOR OF MISSION-CRITICAL PUSH-TO-TALK OVER CELLULAR (POC) HANDSETS AND ACCESSORIES, TODAY ANNOUNCED THAT ITS FLAGSHIP DEVICE, THE SIYATA SD7, HAS EARNED THE "VERIZON FRONTLINE VERIFIED" DESIGNATION, JOINING AN ELITE GROUP OF SOLUTIONS VETTED AND APPROVED FOR USE BY FIRST RESPONDERS OPERATING ON THE VERIZON FRONTLINE NETWORK. READ VERIZON'S OFFICIAL ANNOUNCEMENT HERE: HTTPS://WWW.VERIZON.COM/ABOUT/NEWS/VERIZON-FRONTLINE-WELCOMES-RADIAV-AND-SIYATA "WE ARE PLEASED TO BE RECOGNIZED AS A 'VERIZON FRONTLINE VERIFIED' PARTNER," SAID MARC SEELENFREUND, CEO OF SIYATA.

SIYATA MOBILE'S SD7 DEVICE DESIGNATED AS "VERIZON FRONTLINE VERIFIED"

TORONTO--(BUSINESS WIRE)-- #FORDNATION--HARRY GOSLIN, PRESIDENT OF THE ONTARIO COMPENSATION EMPLOYEES UNION (OCEU/CUPE 1750), WILL JOIN STRIKING WORKPLACE SAFETY AND INSURANCE BOARD (WSIB) WORKERS ON THE PICKET LINE OUTSIDE PREMIER DOUG FORD'S CONSTITUENCY OFFICE AT 823 ALBION ROAD IN ETOBICOKE ON THURSDAY, JULY 3, BETWEEN 10:00 A.M. AND 2:00 P.M. ET. THIS PICKET FOLLOWS NEW REVELATIONS THAT WSIB HAS BEGUN OUTSOURCING CORE WORK PERFORMED BY FRONTLINE UNION MEMBERS, DESPITE AN ONGOING PROVINCE-WIDE STRIKE NOW.

FRONTLINE WSIB WORKERS RALLY AT FORD'S OFFICE AMID GROWING STRIKE TENSIONS

85% REMISSION RATE OBSERVED IN EVALUABLE FRONTLINE AML PATIENTS MIPLETAMIG COMBINATION ENABLES RARE PATHWAY TO TRANSPLANT IN A PREVIOUSLY INELIGIBLE UNFIT PATIENT NO DOSE-LIMITING TOXICITIES OBSERVED AMONG EVALUABLE PATIENTS; SAFETY PROFILE REMAINS STRONG EVIDENCE MOUNTS FOR MIPLETAMIG AS A POTENTIALLY TRANSFORMATIONAL ADDITION TO STANDARD OF CARE IN FRONTLINE AML AS TARGETED CD123 X CD3 APPROACH SHOWING POWER AND PRECISION, LIMITED ADDED TOXICITY MIPLETAMIG TRIAL MOMENTUM BUILDS AS COHORT 3 NEARS FULL ENROLLMENT AT HIGHEST DOSE LEVEL EVALUATED TO DATE IN COMBINATION THERAPY SEATTLE, WA / ACCESS NEWSWIRE / JUNE 18, 2025 / APTEVO THERAPEUTICS ("APTEVO") (NASDAQ:APVO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL BISPECIFIC IMMUNO-ONCOLOGY THERAPEUTICS BASED ON ITS PROPRIETARY ADAPTIR AND ADAPTIR-FLEX PLATFORM TECHNOLOGIES, TODAY ANNOUNCED NEW CLINICAL DATA FROM ITS ONGOING PHASE 1B/2 RAINIER TRIAL EVALUATING MIPLETAMIG, ITS FIRST-IN-CLASS CD123 X CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH STANDARD-OF-CARE VENETOCLAX AND AZACITIDINE (VEN/AZA) FOR NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY. ACROSS TWO TRIALS, THE MIPLETAMIG TRIPLET THERAPY DELIVERED REMISSIONS IN 85% OF EVALUABLE FRONTLINE AML PATIENTS-WHICH SIGNIFICANTLY EXCEEDS RESULTS FROM COMPETITOR STUDIES, INCLUDING THOSE ACHIEVED IN THE VIALE A TRIAL THAT EVALUATEDVENETOCLAX AND AZACITIDINE (VEN/AZA) AS DOUBLET THERAPY.

MIPLETAMIG DEMONSTRATES COMPELLING CLINICAL ACTIVITY IN FRONTLINE AML

FIRST RESPONDERS IN ALL MAJOR MARKETS NOW HAVE ACCESS TO DEDICATED 5G UW NETWORK CAPACITY FIRST RESPONDERS IN ALL MAJOR MARKETS NOW HAVE ACCESS TO DEDICATED 5G UW NETWORK CAPACITY

VERIZON FRONTLINE NETWORK SLICE NOW AVAILABLE NATIONWIDE

WAYNE, PA., JUNE 12, 2025 (GLOBE NEWSWIRE) -- WAYNE, PA.  [JUNE 12, 2025]  FRONTLINE EDUCATION, A LEADING PROVIDER OF ADMINISTRATION SOFTWARE PURPOSE-BUILT FOR EDUCATORS IN K-12,TODAY ANNOUNCED JONATHAN KOST AS CHIEF STRATEGY OFFICER, A NEWLY CREATED POSITION ON THE COMPANY'S EXECUTIVE LEADERSHIP TEAM. HE WILL LEAD FRONTLINE'S STRATEGIC DIRECTION AND INNOVATION EFFORTS TO ACCELERATE GROWTH AND ADVANCE THE COMPANY'S MISSION IN K-12 EDUCATION.

FRONTLINE EDUCATION ANNOUNCES JONATHAN KOST AS CHIEF STRATEGY OFFICER

PRESTIGIOUS INTERNATIONAL AWARDS PROGRAM RECOGNIZES OUTSTANDING EDUCATIONAL TECHNOLOGY PRODUCTS AND COMPANIES PRESTIGIOUS INTERNATIONAL AWARDS PROGRAM RECOGNIZES OUTSTANDING EDUCATIONAL TECHNOLOGY PRODUCTS AND COMPANIES

EDTECH BREAKTHROUGH AWARDS FRONTLINE HCM WITH 2025 EDUCATION ADMINISTRATION SOLUTION OF THE YEAR

SAN CARLOS, CALIF.--(BUSINESS WIRE)---- $ONC #BEONE--BEONE MEDICINES LTD. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), A GLOBAL ONCOLOGY COMPANY, TODAY WILL PRESENT NEW DATA FROM THE ARM C AND D COHORTS OF THE PIVOTAL, GLOBAL PHASE 3 SEQUOIA TRIAL OF BRUKINSA (ZANUBRUTINIB). THE FINDINGS UNDERSCORE THE STRONG AND CONSISTENT EFFICACY OF BRUKINSA ACROSS CLL PATIENT TYPES, INCLUDING HIGH-RISK MUTATION STATUS. THESE DATA WILL BE PRESENTED IN TWO RAPID ORAL PRESENTATIONS AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (A.

BEONE MEDICINES PRESENTS NEW SEQUOIA STUDY RESULTS REINFORCING BRUKINSA'S DIFFERENTIATED PROFILE WITH OR WITHOUT VENETOCLAX IN FRONTLINE CLL AT ASCO 2025

Frontline Ltd.

FRO

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Frontline Ltd.

FRO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

FRO